Lilly and Amylin Terminate Diabetes Alliance - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Lilly and Amylin Terminate Diabetes Alliance



Eli Lilly and Amylin Pharmaceuticals have mutually agreed to end a 10-year alliance relating to the diabetes medication exenatide.

Under the terms of the agreement, full responsibility of the global development and commercialisation of exenatide will be transferred to Amylin. Exenatide is currently marketed as Byetta, but the companies have also developed a long-acting form of the drug called Bydureon. Bydureon received approval in Europe in June 2011, but has yet to be approved by the FDA in the US after receiving a complete response letter.

Meanwhile, Eli Lilly will receive an upfront payment of $250 million and a secured note from Amylin for $1.2 billion plus accrued interest. Amylin will make future revenue sharing payments to Lilly in an amount equal to 15% of global net sales of exenatide products, which Eli Lilly will subtract from the note until the full amount has been paid.

If, however, Bydureon has not received FDA approval by June 30, 2014, Amylin’s revenue sharing obligations will terminate and the company will instead pay Eli Lilly 8% of global net sales of exenatide products. In addition, Amylin will also pay Eli Lilly a $150-million milestone contingent upon the FDA approval of a once-monthly suspension version of exenatide, which is in Phase II trials.

The transfer of commercial operations for exenatide to Amylin will be completed by November 30, 2011 in the US. In other territories, Eli Lilly will transfer responsibility and commercialisation on a market-by-market basis in 2012 and 2013.

"This marks an amicable end to a very productive 10-year collaboration that will continue to benefit many people worldwide," Enrique Conterno, president of Lilly Diabetes, said in a statement. "Lilly remains confident that the resubmission package for Bydureon has addressed the requirements outlined by the FDA and looks forward to Amylin achieving the alliance's long-held goal of making Bydureon available to patients in the US."

The agreement also resolves the outstanding litigation between the two companies. In May 2011, Amylin filed a lawsuit against Eli Lilly for anticompetitive activity after Eli Lilly embarked on a partnership with Boehringer Ingelheim to develop and commercialise a product, which Amylin believes will compete with exenatide.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here